Revenue performance in 2018
On January 8, 2019, Boston Scientific (BSX) issued a press release announcing preliminary unaudited sales for the fourth quarter and 2018.
According to the release, the company has reported unaudited sales of $9.82 billion for 2018, up 8.0% YoY (year-over-year) on an operational basis, up 7.2% YoY on an organic basis, and up 8.6% YoY on a reported basis. This performance is in line with the 2018 revenue guidance of $9.787 billion–$9.827 billion the company provided on its third-quarter earnings conference call.
According to the press release, Boston Scientific reported unaudited sales of $2.56 billion for the fourth quarter of 2018, up 8.2% YoY on an operational basis, up 7% YoY on an organic basis, and up 6.3% YoY on a reported basis. This performance is in line with the 2018 revenue guidance of $2.525 billion–$2.565 billion the company provided on its third-quarter earnings conference call.
Revenue projections for 2019 and 2020
Wall Street analysts expect Boston Scientific to report revenue of $10.66 billion, a YoY rise of 8.57%, in 2019. The company is expected to report revenue of $11.59 billion, a YoY rise of 8.74%, in 2020.
According to Boston Scientific’s 37th Annual J.P. Morgan Healthcare Conference investor presentation, it reported a CAGR (compound average growth rate) of 9% on an operational basis and a CAGR of 8% on an organic basis in its revenue from 2015 to 2016. The company is expected to report operational CAGRs of between 7% and 10% in 2019 and 2020.
In the next article, we’ll discuss key geographic revenue drivers and EPS estimates for Boston Scientific in greater detail.